CHIRON RIBA HCV 3.0 SIA I RIBA HIV-1 HIV-2

Glavna informacija

  • Trgovački naziv:
  • CHIRON RIBA HCV 3.0 SIA I CHIRON RIBA HIV-1/HIV-2 SIA
  • Razred:
  • In vitro dijagnostika - dodatak II, lista A
  • Koristi za:
  • Ljudi
  • Vrsta lijekova:
  • Medicinski uređaj
  • Proizveden od:
  • Novartis Vaccines and Diagnostics, Inc., SAD

Dokument

  • za javnost:
  • Informativni letak za ovaj proizvod trenutno nije dostupan, možete poslati zahtjev na našu službu za korisnike, a mi ćemo vas obavijestiti čim smo u mogućnosti da ga dobiju.


    Zatražite informativni letak za javnost.

Lokalizacija

  • Na raspolaganju u:
  • CHIRON RIBA HCV 3.0 SIA I CHIRON RIBA HIV-1/HIV-2 SIA
    Hrvatska
  • Jezik:
  • hrvatski

Terapeutski informacija

  • Terapijska grupa:
  • potvrdni testovi za dokazivanje antitijela na virus hepatitisa C i na virus HIV-a tipa 1 i 2

Druge informacije

Status

  • Izvor:
  • HALMED Agencija za lijekove i medicinske proizvode - Agency for medicinal products and medical devices of Croatia
  • Broj odobrenja:
  • 381-09-5519
  • Datum autorizacije:
  • 12-03-2009
  • Zadnje ažuriranje:
  • 05-06-2018
  • Informativni letak za ovaj proizvod trenutno nije dostupan, možete poslati zahtjev na našu službu za korisnike, a mi ćemo vas obavijestiti čim smo u mogućnosti da ga dobiju.

    Zatražite informativni letak za javnost.

17-10-2018

Faribault Foods, Inc. Announces Voluntary Recall of a Limited Quantity of S&W Brand White Beans Due to the Presence of Undeclared (Sulfites)

Faribault Foods, Inc. Announces Voluntary Recall of a Limited Quantity of S&W Brand White Beans Due to the Presence of Undeclared (Sulfites)

Faribault Foods, Inc. of Faribault, MN is recalling its 15 ounce S&W White Beans because it contains undeclared sulfites. People who have an allergy or severe sensitivity to sulfites run the risk of serious or life-threatening allergic reaction if they consume this product.

FDA - U.S. Food and Drug Administration

25-7-2018

Pollen allergies and food supplements: ANSES reminds consumers of the precautions to be taken

Pollen allergies and food supplements: ANSES reminds consumers of the precautions to be taken

Cases of allergies associated with the consumption of food supplements are regularly reported to ANSES under its nutrivigilance scheme. Recently, severe allergies following the consumption of food supplements containing hive products (royal jelly, propolis) and pollen have been reported. ANSES reminds consumers that people who are allergic to pollen can potentially be at risk from allergies when consuming foods and food supplements containing products of the beehive.

France - Agence Nationale du Médicament Vétérinaire

10-7-2018

Preventieve HIV-remmers (PrEP) worden verstrekt voor een periode van vijf jaar

Preventieve HIV-remmers (PrEP) worden verstrekt voor een periode van vijf jaar

PrEP wordt binnen een onderzoekssetting voor een periode van vijf jaar verstrekt aan de hoogrisicogroep van mannen die seks hebben met mannen (MSM). Dat heeft minister Bruno Bruins (Medische Zorg) vandaag bekend gemaakt. Op basis van schattingen van het RIVM zullen ongeveer 6500 mannen hiervan gebruik gaan maken en kunnen hiermee  250 hiv-infecties per jaar worden voorkomen. Voor gebruikers gaat een eigen bijdrage gelden van maximaal 25%, dat komt overeen met ongeveer 12 euro per maand. Ook wordt hen gev...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

23-5-2018

FDA Drug Safety Communication: FDA to evaluate potential risk of neural tube birth defects with HIV medicine dolutegravir (Juluca, Tivicay, Triumeq)

FDA Drug Safety Communication: FDA to evaluate potential risk of neural tube birth defects with HIV medicine dolutegravir (Juluca, Tivicay, Triumeq)

The U.S. Food and Drug Administration (FDA) is alerting the public that serious cases of neural tube birth defects involving the brain, spine, and spinal cord have been reported in babies born to women treated with dolutegravir (Juluca, Tivicay, Triumeq) used to treat human immunodeficiency virus (HIV).

FDA - U.S. Food and Drug Administration

13-5-2011

Danish Pharmacovigilance Update, April 2011

Danish Pharmacovigilance Update, April 2011

In this issue of Danish Pharmacovigilance Update, read about a new contraindication for Telzir® (fosamprenavir) for HIV treatment, reports of blood clots from the use of Vivaglobin®, and new, improved e-forms for reporting suspected adverse reactions and much more.

Danish Medicines Agency

7-8-2018

Ribavirin Mylan (Mylan S.A.S.)

Ribavirin Mylan (Mylan S.A.S.)

Ribavirin Mylan (Active substance: Ribavirin ) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5423 of Tue, 07 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1185/T/29

Europe -DG Health and Food Safety

18-5-2018

EU/3/16/1817 (IQVIA RDS Ireland Limited)

EU/3/16/1817 (IQVIA RDS Ireland Limited)

EU/3/16/1817 (Active substance: Human donor haematopoietic stem and progenitor cells that have been treated ex vivo with the protein transduction domain of the HIV-1 transactivation protein fused to MYC transcription factor) - Transfer of orphan designation - Commission Decision (2018)3143 of Fri, 18 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/191/16/T/01

Europe -DG Health and Food Safety